Orion Oyj (OTCMKTS:ORINF) Short Interest Down 54.5% in March

Orion Oyj (OTCMKTS:ORINF) saw a significant decline in short interest in March. As of March 15th, there was short interest totalling 283,700 shares, a decline of 54.5% from the February 28th total of 623,300 shares. Based on an average trading volume of 100 shares, the short-interest ratio is presently 2,837.0 days.

Orion Oyj Stock Performance

OTCMKTS ORINF remained flat at $48.65 during trading hours on Friday. The firm’s fifty day moving average price is $48.65 and its 200-day moving average price is $48.07. Orion Oyj has a 52-week low of $48.65 and a 52-week high of $48.65.

About Orion Oyj

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson’s disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.